- Home
- TRVI vs MMI Comparison
TRVI vs MMI Comparison
Compare TRVI & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- MMI
- Stock Information
- Founded
- TRVI 2011
- MMI 1971
- Country
- TRVI United States
- MMI United States
- Employees
- TRVI N/A
- MMI N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- MMI Real Estate
- Sector
- TRVI Health Care
- MMI Finance
- Exchange
- TRVI Nasdaq
- MMI Nasdaq
- Market Cap
- TRVI 1.1B
- MMI 1.2B
- IPO Year
- TRVI 2019
- MMI 2013
- Fundamental
- Price
- TRVI $10.65
- MMI $29.03
- Analyst Decision
- TRVI Strong Buy
- MMI Hold
- Analyst Count
- TRVI 9
- MMI 1
- Target Price
- TRVI $20.72
- MMI N/A
- AVG Volume (30 Days)
- TRVI 2.0M
- MMI 134.5K
- Earning Date
- TRVI 11-05-2025
- MMI 11-07-2025
- Dividend Yield
- TRVI N/A
- MMI 1.72%
- EPS Growth
- TRVI N/A
- MMI N/A
- EPS
- TRVI N/A
- MMI N/A
- Revenue
- TRVI N/A
- MMI $725,903,000.00
- Revenue This Year
- TRVI N/A
- MMI $9.50
- Revenue Next Year
- TRVI N/A
- MMI $17.73
- P/E Ratio
- TRVI N/A
- MMI N/A
- Revenue Growth
- TRVI N/A
- MMI 17.89
- 52 Week Low
- TRVI $2.36
- MMI $27.35
- 52 Week High
- TRVI $11.11
- MMI $42.80
- Technical
- Relative Strength Index (RSI)
- TRVI 71.22
- MMI 44.25
- Support Level
- TRVI $9.29
- MMI $27.40
- Resistance Level
- TRVI $10.04
- MMI $28.33
- Average True Range (ATR)
- TRVI 0.57
- MMI 0.67
- MACD
- TRVI 0.07
- MMI 0.09
- Stochastic Oscillator
- TRVI 82.67
- MMI 65.53
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About MMI Marcus & Millichap Inc.
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.